DEA and HHS Extend Telemedicine Flexibilities through 2025

DEA addressed the status of telemedicine prescribing flexibilities including state reciprocity (DEA-DC-018 EO-DEA067) and medications for opioid use disorder prescribed by telephone (DEA-DC-022 EO-DEA068) in the temporary rule titled “Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications” which published in the Federal Register on May 10, 2023. 88 FR 30042. With respect to practitioner patient relationships formed after the May 11, 2023, expiration of the COVID–19 PHE, a third temporary rule will extend these exceptions until December 31, 2025, or until DEA publishes a Final Rule on Telemedicine. 89 FR 91253. See also 21 C.F.R. 1307.41.

DEA extends telemedicine flexibilities through 2025. Click here to read more.